vimarsana.com
Home
Live Updates
Olema Oncology Reports Fourth Quarter and Full-Year 2023 : comparemela.com
Olema Oncology Reports Fourth Quarter and Full-Year 2023
Presented compelling clinical results for palazestrant both as a monotherapy and in combination with CDK4/6 inhibitors, ribociclib and palbociclib, in Q4...
Related Keywords
Massachusetts ,
United States ,
San Francisco ,
California ,
Spain ,
Madrid ,
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Berlin ,
Germany ,
Geoffrey Mogilner ,
Seanp Bohen ,
Nasdaq ,
Breast Cancer Annual Congress ,
Novartis Institutes For Biomedical Research Inc ,
Silicon Valley Bank ,
Securities Exchange ,
Novartis ,
Drug Administration ,
Olema Pharmaceuticals Inc ,
European Society For Medical Oncology ,
Exchange Commission ,
Cancer Annual Congress ,
Chief Executive Officer ,
Cancer Annual ,
Antonio Breast Cancer Symposium ,
European Society ,
Medical Oncology ,
Novartis Institutes ,
Biomedical Research ,
Investigational New Drug ,
Fast Track ,
Securities Act ,
Securities Exchange Act ,
Annual Report ,
Consolidated Statements ,
Months Ended December ,
Media Contact ,
Vice President ,
Investor Relations ,
Nasdaq Olma ,
Olema Pharmaceuticals ,
Nc ,
Biotech ,
Earnings ,
Selma ,
Breast Cancer ,
comparemela.com © 2020. All Rights Reserved.